Press Releases

Date Title and Summary
Toggle Summary Isis Pharmaceuticals Reports Financial Results and Highlights for the Year 2002
Toggle Summary Isis Pharmaceuticals Earns Second Milestone in Amgen Antisense Drug Discovery Collaboration
Toggle Summary Webcast Alert: Isis Conference Call
Toggle Summary Isis Pharmaceuticals Enters Into Target Validation Agreement With Pfizer
Toggle Summary Isis Pharmaceuticals and atugen AG Enter Patent License Agreement
Toggle Summary Isis Pharmaceuticals Reacquires ISIS 113715 Type 2 Diabetes Drug from Merck
Toggle Summary Isis Pharmaceuticals Reports New Data From Phase II Clinical Trial Of ISIS 2503 Plus Chemotherapy in Pancreatic Cancer
Toggle Summary OncoGenex Technologies and Isis Pharmaceuticals Achieve Alliance Milestone: Initiate Phase I Clinical Trial of Antisense Drug in Prostate Cancer
Toggle Summary Isis Pharmaceuticals and GlaxoSmithKline Enter Into Target Validation Agreement
Toggle Summary Isis Pharmaceuticals Statement Regarding UBS Warburg Report
Toggle Summary Isis Pharmaceuticals Initiates Phase II Clinical Trial of Alicaforsen, ISIS 2302, in Patients With Ulcerative Colitis
Toggle Summary New Data on Capsule Form of ISIS 104838 Demonstrate Antisense Drugs Can Be Administered Orally Orasense Joint Venture Makes Fundamental Advance in Antisense Technology
Toggle Summary Isis Pharmaceuticals and Elan Corporation Conclude Collaboration In HepaSense Joint Venture and Restructure OraSense Collaboration
Toggle Summary Isis Pharmaceuticals Reports Third Quarter And Year-To-Date 2002 Financial Results
Toggle Summary Webcast Alert: Isis Conference Call
Toggle Summary New Phase II Data Confirm ISIS 14803 Produces Significant Viral Level Reductions in Patients With Drug-Resistant Hepatitis C
Toggle Summary Webcast Alert: Isis Conference Call
Toggle Summary Alicaforsen (ISIS 2302) Improves Potential for Responses and Remissions
Toggle Summary Isis Pharmaceuticals to Manufacture Affinitac™ for Eli Lilly and Company
Toggle Summary Isis Receives 1,000th Patent
Toggle Summary Isis Pharmaceuticals and Sequitur Settle Patent Infringement Lawsuit; Sequitur Licenses Isis' Intellectual Property for Functional Genomics
Toggle Summary Isis Pharmaceuticals and Hybridon Cancel Remaining Reciprocal Financial Obligations From Intellectual Property Transaction
Toggle Summary Isis Pharmaceuticals Achieves Milestone In Amgen Antisense Drug Discovery Collaboration
Toggle Summary Isis Pharmaceuticals Reports Second Quarter 2002 Highlights and Financial Results
Toggle Summary Isis Pharmaceuticals Discusses Second Quarter Financial Results
Toggle Summary Isis Pharmaceuticals Continues to Strengthen Balance Sheet by Prepaying $19.7 Million of 12% Convertible Debt Held By Elan
Toggle Summary Webcast Alert: Isis Pharmaceuticals, Inc. Discusses Debt Retirement Progress On the Web; Live and Archived Conference Call Notification
Toggle Summary Isis Pharmaceuticals Initiates European Phase III Clinical Trial Of Alicaforsen, ISIS 2302, in Crohn's Disease
Toggle Summary Isis and Lilly Broaden Antisense Alliance To Include Discovery of Cancer Treatments
Toggle Summary Spencer R. Berthelsen, M.D., F.A.C.P., Elected to Isis Pharmaceuticals' Board of Directors
Toggle Summary Webcast Alert: Isis Pharmaceuticals, Inc. Open House Presentation
Toggle Summary Issuance of Pivotal Patent Provides Isis Pharmaceuticals Therapeutic Control Over Third-Generation Antisense Chemistry
Toggle Summary Isis Pharmaceuticals Expands Therapeutic Potential of Antisense Technology To Cardiovascular Disease
Toggle Summary New Affinitac(TM) Data in Non-Small Cell Lung Cancer Presented at ASCO
Toggle Summary Isis Pharmaceuticals Achieves $3.75 Million Development Milestone In HepaSense Joint Venture With Elan Corporation
Toggle Summary Isis Pharmaceuticals Announces Pricing of Convertible Subordinated Notes
Toggle Summary Isis Pharmaceuticals to Make Early Payment of $74 Million of 14% Senior Subordinated Debt
Toggle Summary Isis Pharmaceuticals Announces Convertible Debt Offering
Toggle Summary Isis Pharmaceuticals Reports First Quarter 2002 Highlights and Financial Results
Toggle Summary Webcast Alert: Isis Pharmaceuticals, Inc. to Discuss Its 2002 First Quarter Financial Results on the Web; Live and Archived Conference Call Notification
Toggle Summary Isis Pharmaceuticals and Merck Extend Hepatitis C Drug Discovery Collaboration for a Second Time
Toggle Summary Isis Pharmaceuticals Reports Preliminary Phase II Data On ISIS 2503 Plus Chemotherapy in Pancreatic Cancer
Toggle Summary Isis Pharmaceuticals' Ibis Therapeutics Division Awarded New $2.4 Million Government Contract to Advance Its Antibacterial Drug Discovery Program
Toggle Summary Issuance of Key Second-Generation Antisense Patent Further Strengthens Isis' Intellectual Property Estate
Toggle Summary Isis Pharmaceuticals Announces Adoption of Securities Trading Plan Under SEC Rule 10b5-1
Toggle Summary Isis Pharmaceuticals' GeneTrove Division Enters Into Target Validation Collaboration and Patent License Agreement With Pharmacia Corporation
Toggle Summary HepaSense Initiates Phase II Clinical Trial of ISIS 14803 in Hepatitis C
Toggle Summary Isis Pharmaceuticals Initiates Phase II Clinical Trial of ISIS 104838, A TNF-Alpha Inhibitor, in Rheumatoid Arthritis
Toggle Summary Dr. John C. Reed Elected to Isis Pharmaceuticals' Board of Directors
Toggle Summary Isis Pharmaceuticals Reports Phase II Study Results Of Topical Alicaforsen, ISIS 2302, in Psoriasis
Toggle Summary Isis Pharmaceuticals Changes Ticker Symbol
Toggle Summary Isis Pharmaceuticals' GeneTrove(TM) Division Initiates Target Validation Collaboration With Merck & Co., Inc.
Toggle Summary Isis Pharmaceuticals Announces Plans to Change Ticker to 'ISIS'
Toggle Summary Isis Pharmaceuticals Reports Financial Results And Highlights for the Year 2001
Toggle Summary Webcast Alert: Isis Pharmaceuticals, Inc. Announces Its Fourth Quarter Financial Results on the Web;
Toggle Summary Enrollment Completed in Major Lung Cancer Trial
Toggle Summary Isis Pharmaceuticals And Eyetech Pharmaceuticals Sign Intellectual Property License Agreement
Toggle Summary Isis Pharmaceuticals And Amgen Enter Into Target Validation And Patent License Agreement